Navigation Links
Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
Date:11/10/2008

e information about Cardium's Tissue Repair Company subsidiary, please visit http://www.t-r-co.com.

Cardium's Generx product candidate (alferminogene tadenovec, Ad5FGF-4) is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium Therapeutics and its businesses, products and therapeutic candidates, please visit http://www.cardiumthx.com or view its 2007 Annual Report at http://www.cardiumthx.com/flash/pdf/CardiumAR07_Book_FINAL.pdf.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, that human clinical trials can be conducted and completed in an efficient and successful manner, that FDA, CE Mark or other regulatory clearances or UL or other certifications, or partnering or other distribution agreements or other commercialization efforts will be successful or will effectively accelerate the business or market, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that our products or product candidates will prove to be sufficiently safe and effective, that necessary regulatory approvals will be obtaine
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
2. ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels
3. Cardium Announces InnerCools New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification
4. Cardium Announces Follow-On Direct Investment by Institutional Investor
5. Cardium Selected for Inclusion in Russell Microcap Index
6. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
7. Cardium Launches New AWARE Clinical Study Website
8. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
9. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
10. Cardium Reports on First Quarter 2008 Highlights and Financial Results
11. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Currently offering a comprehensive portfolio ... Weighing, Rice Lake, and Ohaus, Pipette.com has added ... Sartorius CPA Semi-Micro Balance is ideal for lab ... user-friendly laboratory balance. , Sartorius is a global ... balances are well known for their high performance, ...
(Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
(Date:10/20/2014)... 2014 Mapp Biopharmaceutical,s valiant effort to ... to fight the Ebola outbreak will make the ... production of pharmaceuticals can be, according to Kalorama ... while some may be taken aback by the ... industry knowledge are well aware of the complex ...
(Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2
... Vaccine Induced Neutralizing Antibodies and Protected Mice upon ChallengeROCKVILLE, ... NVAX ) announced results from a preclinical study of ... the viral fusion (F) protein. The virus utilizes ... respiratory tract and cause illness. Novavax,s RSV-F ...
... Boston Scientific Corporation (NYSE: BSX ) ... ended December 31, 2008. Subsequent to the release ... a patent litigation settlement and, as expected, finalized a ... U.S. Generally Accepted Accounting Principles, these events are required ...
... 26 InterMune, Inc.,(Nasdaq: ITMN ) today announced ... December 31, 2008. InterMune reported a net loss for ... share, compared with a,net loss of $25.9 million, or $0.67 ... Dan Welch, Chairman, Chief Executive Officer and ...
Cached Biology Technology:NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate Directed Against the Fusion (F) Protein 2NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate Directed Against the Fusion (F) Protein 3NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate Directed Against the Fusion (F) Protein 4Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 2Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 3Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 4Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 5Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 6Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 7Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 8Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 9Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 10InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 2InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 3InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 4InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 5InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 6InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 7InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 8InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 9InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 10InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 11InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 12
(Date:10/16/2014)... human body. Battles are won, lost or sometimes ... stalemate—known as tumor dormancy—can last up to 25 ... is poorly understood. , A new computational ... a Professor of Chemistry at Princeton University, may ... the switch to a malignant state. Published today ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
(Date:10/15/2014)... of Life, is a non-traditional biophysics textbook and it ... is a journey of discovery into biological systems and ... biological regulation. It is about how our genes make ... the billions of cells in an organism. It quantifies ... principles, which can be found on both large and ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2
... awarded a three-year grant from the U.S. Department ... economic impacts of the "biofuels revolution" on rural ... comes from the department,s Ethical, Legal and Societal ... Genomes or Nanotechnologies program. The researchers from K-State,s ...
... have a soft spot for Botswana, developed while reading ... have had a chance to do any sleuthing of ... when University of Illinois scientist Karen Chapman-Novakofski acquired a ... about the health and nutrition of that country,s elderly. ...
... at the University of Leeds have made a breakthrough ... greatest global disease threats to wild carnivores including lions, ... The discovery of how canine distemper Virus (CDV) jumps ... to a more effective monitoring and control of the ...
Cached Biology News:K-State sociologists use Department of Energy grant 2U of I scientist does nutritional detective work in Botswana 2U of I scientist does nutritional detective work in Botswana 3Research sheds new light on how diseases jump across species 2
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Epi-Grids™ Colony Grid Templates are easy-to-use griding templates that allow rapid organization of colonies from initial screening plates and for preparing precise master plates....
Biology Products: